The role of estrogen and progesterone,

administered alone and in combination, in

modulating cytokine concentration following

traumatic brain injury by Khaksari, Mohammad et al.
The role of estrogen and progesterone,
administered alone and in combination, in
modulating cytokine concentration following
traumatic brain injury
Mohammad Khaksari, Zahra Soltani, Nader Shahrokhi, Gholamreza Moshtaghi, and
Gholamreza Asadikaram
Abstract: Cytokines play an important role in the pathophysiology of traumatic brain injury (TBI). This study was de-
signed to determine the effects of administering progesterone (P) and estrogen (E), alone and in combination, on brain
water content, blood–brain barrier (BBB) disturbance, and brain level of cytokines following diffuse TBI. Ovariectomized
rats were divided into 9 groups, treated with vehicle, E1, E2, P1, P2, E1+P1, E1+P2, E2+P1, and E2+P2. Levels of BBB
disruption (5 h), cytokines, and water content (24 h) were evaluated after TBI induced by the Marmarou method. Physio-
logical (E1 and P1) and pharmacological (E2 and P2) doses of estrogen and progesterone were administered 30 min after
TBI. Water content in the E1+P2-treated group was higher than in the E1-treated group. The inhibitory effect of E2 on
water content was reduced by adding progesterone. The inhibitory effect of E1 and E2 on Evans blue content was reduced
by treatment with E1+P1 and E2+P2, respectively. The brain level of IL-1b was reduced in E1 and E2, after TBI. In the
E2+P2-treated group, this level was higher than in the E2-treated group. The brain level of TGF-b was also elevated by
the administration of progesterone and estrogen alone, and reduced when the hormones were administered in combination.
In conclusion, a combined administration of progesterone and estrogen inhibited the decreasing effects of administration of
progesterone and estrogen alone on water content and BBB disruption that mediated to change the proinflammatory cyto-
kines.
Key words: estrogen, progesterone, traumatic brain injury, blood–brain barrier, water content, cytokines.
Re´sume´ : Les cytokines jouent un roˆle important dans la pathophysiologie de la le´sion ce´re´brale traumatique (TCC). La
pre´sente e´tude a eu pour but de de´terminer les effets de l’administration de progeste´rone (P) ou d’œstroge`ne (E), se´pare´-
ment ou en association, sur la teneur en eau, l’alte´ration de la barrie`re he´mato-ence´phalique (BHE) et le taux de cytokines
dans le cerveau apre`s une TCC diffuse. On a divise´ des rats ovariectomise´s (OVX) en 9 groupes : ve´hicule, E1, E2, P1,
P2, E1+P1, E1+P2, E2+P1 et E2+P2. On a e´value´ les taux d’alte´ration de la BHE (5 h), les taux de cytokines et la teneur
en eau (24 h) apre`s une TCC induite par la me´thode Marmarou. On a administre´ des doses physiologiques (E1 et P1) et
pharmacologiques (E2 et P2) d’œstroge`ne et de progeste´rone 30 min apre`s la TCC. La teneur en eau a e´te´ plus e´leve´e
chez E1+P2 que chez E1. L’effet inhibiteur de E2 sur la teneur en eau a e´te´ atte´nue´ par l’ajout de progeste´rone. L’effet in-
hibiteur de E1 et de E2 sur la teneur en bleu d’E´ vans a e´te´ diminue´ par E1+P1 et E2+P2 respectivement. Le taux ce´re´bral
d’IL-1b a diminue´ chez E1 et E2 apre`s la TCC. Ce taux a e´te´ plus e´leve´ chez E2+P2 que chez E2. Le taux ce´re´bral de
TGB-b a aussi e´te´ augmente´ par l’administration se´pare´e de progeste´rone et d’œstroge`ne, et diminue´ par l’administration
combine´e des hormones. Ainsi, l’administration combine´e de progeste´rone et d’œstroge`ne a inhibe´ les effets de´croissants
de l’administration se´pare´e de progeste´rone et d’œstroge`ne sur la teneur en eau et l’alte´ration de la BHE, et conduit aux
modifications des cytokines proinflammatoires.
Mots-cle´s : œstroge`ne, proge´sterone, le´sion ce´re´brale traumatique, barrie`re he´mato-ence´phalique, teneur en eau, cytokines.
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Introduction
In postmenopausal women, the incidence of stroke rapidly
increases (Wenger et al. 1993), coincident with diminished
circulating levels of estrogen and progesterone. Estrogens
function as neurotrophic molecules and prevent neuronal
cell death under certain conditions. Recent evidence sug-
gests that progesterone may also contribute to these events,
albeit to a lesser extent (Hoffman et al. 2006).
Brain trauma produces edema, primary death of neurons
at the site of impact and secondary neuronal damage to the
underlying area. Focusing on the role of gonadal steroids in
brain trauma began with the observation that following trau-
matic injury, females showed less edema than males (Roof
et al. 1993). The investigators then concentrated on proges-
terone because in the state of hyperprogesteronemia in fe-
males, edema was virtually absent (Roof et al. 1993).
Subsequent studies showed the protective effects of proges-
terone in males by examining both edema and cognitive re-
covery (Roof et al. 1994). Additionally, a recent study
showed that progesterone at low but not high physiological
levels protected against secondary injury to the hippocampus
following brain injury (Robertson et al. 2006). It has also
been shown that administration of physiological (Dubal and
Wise 2001) or pharmacological (Simpkins et al. 1997) levels
of estrogen following cerebral ischemia dramatically reduces
ischemic volume. Indeed, in some studies it was shown that
exogenous progesterone has a dose- and time-dependent
neuroprotective action in experimental stroke (Murphy et al.
2002). The role of estrogens in traumatic brain injury has
not been well illuminated, while a neuroprotective role for
estrogens in cerebral ischemia has been suggested (Stein et
al. 2008).
Cerebrovascular inflammation is an early event in the
pathogenesis of stroke, and in secondary brain injury is be-
lieved to contribute by promoting leukocyte infiltration into
brain (Frijns and Kappelle 2002), and blood–brain barrier
(BBB) injury (del Zoppo and Hallenbeck 2000), and vaso-
genic edema (de Vries et al. 1997). The inflammation begins
through the synthesis of cytokines, which signals the induc-
tion of proinflammatory mediators (Ospina et al. 2004). The
disturbances of brain cytokines and growth factors including
interleukin (IL)-1b and transforming growth factor-b (TGF-
b) were implicated in the post-traumatic inflammatory cas-
cade in earlier studies (Olsson 1995; de Vries et al. 1997;
Hans et al. 1999).
Estrogens have a potent anti-inflammatory effect (Ospina
et al. 2004) with regard to cerebral vascular response to IL-
1b, while progesterone reduces cerebral edema by attenutat-
ing the production of proinflammatory cytokines (IL-1b,
TNF-a) after TBI (He et al. 2004). An in vitro study also
revealed that progesterone and estrogens reduce IL-b
mRNA levels in monocytes (Polan et al. 1989).
The increased incidence of stroke and cerebral edema
after menopause and in ovariectomized female animals is
compatible with diminished circulating levels of estrogen
and progesterone. While progesterone showed an anti-
inflammatory effect, this effect is synergic when estrogens
and progesterone are present together (Tibbetts et al.
1999). On the other hand, physiological levels of proges-
terone led to an increase in the inflammatory cytokines in
multiple sclerosis (Hoffman et al. 2001; Koski et al. 2004),
but when estrogen and progesterone were combined, the
damage was limited (Hoffman et al. 2001) and progester-
one receptor expression was up-regulated in the brain
(Murphy et al. 2002). The present investigation was carried
out to analyze brain edema and the intracerebral concentra-
tions of proinflammatory cytokines (IL-b and TGF-b) in
response to administration of progesterone and estrogen
(physiological and pharmacological levels), alone and in
combination, following diffuse traumatic brain injury in
ovariectomized female rats.
Materials and methods
Animals
This study was conducted in accordance with the guide-
lines for the animal experimental protocols of Kerman Uni-
versity of Medical Sciences. The protocol was approved by
the ethics committee (No EC/KNRC/86–30) of this univer-
sity, in accordance with the internationally accepted princi-
ples for laboratory animal use and care, as found in the
European Community guidelines (EEC Directive of 1986;
86/609/EEC) or US guidelines (NIH publication #85–23, re-
vised in 1985). Animals (mature female Albino N Mary rats,
weighing 200–250 g) were housed in an air-conditioned
room at 22–25 8C, with a 12 h light : 12 h dark cycle and
free access to food and water.
Method of bilateral ovariectomy
The animals were first anesthetized by injection of 60 mg/
kg thiopental (intraperitoneal). The subabdominal area of the
body was then shaved and an incision of 2 cm was made.
The skin, fascia, and abdominal muscles were opened. Fats
and intestine were sheered off until the uterus and its tubes
were exposed. Catgut 4 thread was then twisted around the
tube of the uterus and vascular base of the ovaries in the
proximal area and cut from the distal area. We then poured
1–2 mL saline solution into the abdomen and the muscles
and skin were replaced. The incision was stitched using 0–2
silk thread and the wound was washed with Betadine solu-
tion. To avoid interference due to the estrus cycle, all exper-
imental animals were ovariectomized (OVX) 2 weeks before
the experiments (Crandall et al. 2006).
Experimental protocols
Before the OVX animals were injured using the TBI tech-
nique, they were randomly divided into 9 groups, as follows:
(i) Vehicle-treated group: OVX rats received an injection of
an equal volume of vehicle (benzyl alcohol and sesame oil,
which were used as estrogen or progesterone solvent), after
TBI; (ii) E1-treated group: animals received an injection of
a physiological dose of estrogen (33.3 mg/kg); (iii) E2-
treated group: rats received an injection of a pharmacologi-
cal dose of estrogen (1 mg/kg); (iv) P1-treated group: rats
received an injection of a physiological dose of progesterone
(1.7 mg/kg); (v) P2-treated group: rats received an injection
of a pharmacological dose of progesterone (8 mg/kg); (vi)
E1+P1-treated group: rats received an injection of combined
physiological doses of estrogen and progesterone; (vii)
E1+P2-treated group: rats received an injection of a com-
bined physiological dose of estrogen and a pharmacological
32 Can. J. Physiol. Pharmacol. Vol. 89, 2011
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dose of progesterone; (viii) E2+P1-treated group: rats re-
ceived an injection of a combined pharmacological dose of
estrogen and a physiological dose of progesterone; and (ix)
E2+P2-treated group: rats received an injection of combined
pharmacological doses of estrogen and progesterone.
It should be mentioned that the doses of estrogen and pro-
gesterone were given as a single intraperitoneal injection
(i.p.), half an hour after TBI (O’Connor et al. 2005).
Model of diffuse traumatic brain injury (TBI)
All animals were intubated before TBI. The TBI method
was moderate and of the diffuse type induced by the Mar-
marou method (O’Connor et al. 2005), using a TBI induc-
tion device made by the Dept. of Physiology, Kerman
University of Medical Sciences. The protocol was as fol-
lows: a 250 g weight was dropped from a 2 m height onto
the head of the anesthetized (with ether) rat while a metal
disc (stainless steel, 10 mm in diameter, 3 mm thick) was
attached to the animal’s skull. After induction of the trauma,
the rats were immediately connected to a respiratory pump
(TSA animal respiratory compact, Germany). After sponta-
neous breathing had been restored, the intratracheal tube
was removed and, following recovery, the rats were placed
in individual cages.
Determination of brain water content
The brain edema of each animal was assessed by measur-
ing brain water content. Anesthetized animals were sacri-
ficed by cervical dislocation 24 h after TBI, the brain was
removed, and brain samples were placed in pre-weighed
glass vials and weighed (wet weight). The lids were re-
moved and the vials placed in an incubator (Memmert, Ger-
many) at 60 8C for 72 h, and then reweighed (dry weight).
The percentage of water in each sample was then calculated
using a formula published previously (Galani et al. 2001;
O’Connor et al. 2005): (100  [(wet weight–dry weight)/
wet weight]).
Determination of blood–brain barrier (BBB) disruption
The degree of BBB disruption was assessed by measuring
Evans blue dye leakage (O’Connor et al. 2005), with a slight
modification. Briefly, Evans blue dye was dissolved in
0.01 mol/L PBS at a concentration of 2%, then the dye
(2 mL/kg i.v.) was injected into the tail vein 4 h after TBI,
as a BBB permeability tracer. The rats were then deeply
anesthetized with ether and transcardiac perfused with
200 mL heparinized saline through the left ventricle to re-
move the intravascular dye. The brains were removed, then
dissected, weighed, and stored at –80 8C for quantitative
measurement. Brain samples were homogenized in 1 mL of
0.1 mol/L PBS, and 0.7 mL of 100% (w/v) trichloroacetic
acid was added to it, and centrifuged. After centrifugation
Fig. 1. (a) Brain water content (%) after traumatic brain injury in
ovariectomized (OVX) rats (n = 7 in each group). ***, p < 0.001,
all groups vs. Vehicle. # # #, p < 0.001, E2 vs. all groups. (b)
Changes in percentage of water content after TBI compared with
vehicle in OVX rats (n = 7 in each group). **, p < 0.01, E1 vs.
E1+P2 group. *, p < 0.05, E1+P1 vs. E1+P2 group. (c) Changes in
percentage of water content after TBI compared with vehicle, in
OVX rats (n = 7 in each group). {{{, p < 0.001, E2 vs. E2+P1 or
E2+P2 groups. Veh, vehicle; E1, physiological dose of estrogen;
E2, pharmacological dose of estrogen; P1, physiological dose of
progesterone; P2, pharmacological dose of progesterone; E1+P1,
physiological dose of estrogen + physiological dose of progester-
one; E1+P2, physiological dose of estrogen + pharmacological dose
of progesterone; E2+P1, pharmacological dose of estrogen + phy-
siological dose of progesterone; E2+P2, pharmacological dose of
estrogen + pharmacological dose of progesterone. Data are pre-
sented as mean ± SEM.
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for 30 min at 1000g, the absorbance of Evans blue in super-
natant was measured at 610 nm using a spectrophotometer
(UV/VIS, Spectrometer, UK). The amount of extravasated
Evans blue dye was quantified as mg/g brain tissue.
Measurement of brain cytokines and hormones
Rats were given an overdose of thiopental (50 mg/kg i.p.)
24 h after TBI (Dubal et al. 2001; Holmin and Ho¨jeberg
2004) and perfused intracardially with PBS (pH, 7.4) for
1 min to remove the vesicular blood, which might have
contained cytokines from the periphery. The brains were
then quickly removed and immediately frozen in liquid
nitrogen. The brains were weighed and homogenized in
T-PER Tissue Protein Extraction Reagent (Taupin et al.
1993) with 0.5% Triton X-100, 150 mmol/L NaCl,
50 mmol/L Tris, and a protease inhibitor cocktail (Pierce)
(500 mg tissue per 1 mL of the reagent). Following ho-
mogenization, the samples were shaken in a shaker for
90 min and then centrifuged (4 8C and 4000g) for 15 min.
The homogenate supernatant was collected. The protein
content of the supernatant was estimated using a BCA Pro-
tein Assay Reagent Kit to ensure that an equal amount of
protein from each sample was used for the assay (Taupin
et al. 1993). ELISA kits for IL-1b and TGF-b were pur-
chased from Austrian BMS. Evaluation of cytokines was
carried out following protocols provided by the manufac-
turer. The concentration of the cytokines was quantified as
a picogram or nanogram of antigen per milligram of pro-
tein.
Statistical analysis
Quantitative data were expressed as mean ± SEM. The
data were analyzed by parametric analysis of variance
(ANOVA) or independent t test. One-way ANOVA was
used for concentration analysis and an independent t test
was used for a percent analysis of the changes. Fisher’s
LSD was employed for the ANOVA post-hoc analysis
and Levene’s Test for independent t test post-hoc analysis.
The criterion for statistical significance was set at
p < 0.05.
Results
Brain water content
Changes in the brain water content of the ovariectomized
rats are shown in Fig. 1. Fig. 1a shows that the water con-
tent in the groups treated with high (E2) and low (E1) doses
of estrogen and high (P2) and low (P1) doses of progester-
one was significantly lower than that in the vehicle-treated
group (78.84% ± 0.27, p < 0.001). In addition, the water
content in the E2 (70.8% ± 0.19)-treated group was statisti-
cally different from the other treated groups (p < 0.001).
Fig. 1b shows the effect of a low dose of estrogen on brain
water content compared with the vehicle-treated group. A
low dose of estrogen decreased brain water content
Fig. 2. (a) Quantitative measurement of Evans blue content (mg/g
tissue) after traumatic brain injury (TBI) in ovariectomized (OVX)
rats (n = 7 in each group). **, p < 0.01, E1, P1, and P2 groups vs.
Vehicle. ***, p < 0.001, E2 group vs. Vehicle. #, p < 0.05, E1 vs.
P1 group. # # #, p < 0.001, P2 vs. all groups. (b) Changes in per-
centage of Evans blue content after TBI compared with vehicle, in
OVX rats (n = 7 in each group). *, p < 0.05, E1 group vs. E1+P1.
(c) Changes in percentage of Evans blue content after TBI com-
pared with vehicle, in OVX rats (n = 7 in each group). {{{,
p < 0.001, E2 vs. E2+P2 group. {{, p <0.01, E2+P1 vs. E2+P2
group. Veh, vehicle; E1, physiological dose of estrogen; E2, phar-
macological dose of estrogen; P1, physiological dose of progester-
one; P2, pharmacological dose of progesterone; E1+P1,
physiological dose of estrogen + physiological dose of progester-
one; E1+P2, physiological dose of estrogen + pharmacological dose
of progesterone; E2+P1, pharmacological dose of estrogen + phy-
siological dose of progesterone; E2+P2, pharmacological dose of
estrogen + pharmacological dose of progesterone. Data are pre-
sented as mean ± SEM.
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(–2.63% ± 0.5) compared with the E1+P2 (0.97% ± 0.68,
p < 0.01)-treated group. The effect of the E1+P2 treatment
on water content was also statistically different from that
of the E1+P1 group (–1.42% ± 0.75, p < 0.05). Changes
in brain water content in the group treated with a high
dose of estrogen compared with the vehicle-treated group
are shown in Fig. 1c. Water content in the E2 (–10.19% ±
0.37)-treated group was significantly less than in the
E2+P1 (–1.06 ± 0.63, p < 0.001) and E2+P2 (–2.15 ±
0.69, p < 0.001)-treated groups.
Extravasation of Evans blue content
The effect of different doses of ovarian steroid hormones
on BBB disruption after TBI is shown in Fig. 2. Fig. 2a
shows that the Evans blue content in the E1 (27.03 ±
0.32 mg/g tissue, p < 0.001), E2 (26.7 ± 1.09 mg/g tissue,
p < 0.01), and P1 (28.6 ± 0.52 mg/g tissue, p < 0.01)-treated
groups was significantly lower than that of the vehicle-
treated group, while the Evans blue content in the P2
(46.05 ± 1.06 mg/g tissue, p < 0.01)-treated group was sig-
nificantly higher than in the vehicle-treated group. The P2
group increased its Evans blue content, compared with all
the other groups (p < 0.001). The Evans blue content in the
E1 group was also lower than in the P1 group (p < 0.05).
Fig. 2b shows the effect of a low dose of estrogen on Evans
blue content compared with the vehicle-treated group. The
E1 group showed a significant decrease in Evans blue con-
tent (–21.85% ± 1.23) compared with the E1+P1 (–8.57% ±
4.49)-treated group (p < 0.05). The change in the Evans blue
content in the group treated with a high dose of estrogen
compared with the vehicle-treated group is shown in
Fig. 2c. The level of Evans blue decreased in the E2
(–20.81% ± 3.87)-treated group, while this level increased
in the E2+P2 (13.17% ± 5.83)-treated group. There was a
significant difference in the level of Evans blue content be-
tween the E2+P2-treated group and the E2 (p < 0.001) and
E2+P1 (p < 0.01)-treated groups, as well.
Brain level of IL-1b following treatment
The effect of different doses of ovarian steroid hormones
on the brain level of IL-1b after TBI is shown in Fig. 3. Fig.
3a shows that the injured animals treated with either E1
(224.62 ± 32.8 pg/mL) or E2 (223.6 ± 30.1 pg/mL) had a
lower level of IL-1b compared with the vehicle-treated ani-
mals (p < 0.05). Fig. 3b shows the effect of a low dose of
estrogen on the brain IL-1b level compared with that in the
vehicle-treated group. The inhibitory effect of E1+P1
(–55.64% ± 11.44) treatment on IL-1b level was statisti-
cally higher than in the E1+P2 (–11.93% ± 3.94)-treated
group (p < 0.01). The change in the brain level of IL-1b
Fig. 3. (a) The effect of estrogen or progesterone following trau-
matic brain injury (TBI) on brain levels of IL-1b (pg/mL) in ovar-
iectomized (OVX) rats (n = 7 in each group). *, p < 0.05, E1 or E2
groups vs. Vehicle. (b) Changes in the percentage of brain level of
IL-1b after TBI compared with the vehicle, in OVX rats (n = 7 in
each group). **, p < 0.01, E1+P1 vs. E1+P2 group. (c) Changes in
the percentage of brain level of IL-1b after TBI compared with the
vehicle, in OVX rats (n = 7 in each group). ***, p < 0.001, E2+P1
vs. E2+P2 group. {, p < 0.05, E2 vs. E2+P2 group. Veh, vehicle;
E1, physiological dose of estrogen; E2, pharmacological dose of
estrogen; P1, physiological dose of progesterone; P2, pharmacolo-
gical dose of progesterone; E1+P1, physiological dose of estrogen +
physiological dose of progesterone; E1+P2, physiological dose of
estrogen + pharmacological dose of progesterone; E2+P1, pharma-
cological dose of estrogen + physiological dose of progesterone;
E2+P2, pharmacological dose of estrogen + pharmacological dose
of progesterone. Data are presented as mean ± SEM.
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in the group treated with a high dose of estrogen compared
with the vehicle-treated group is shown in Fig. 3c. The in-
hibitory effect of E2 on IL-1b (–21.56% ± 13.6) was
higher than in the E2+P2 (13.35% ± 5.84)-treated group
(p < 0.05). There was also a statistically significant differ-
ence between the E2+P1 (–16.9% ± 7.98)-treated group
and the E2+P2-treated group (p < 0.001).
Brain level of TGF-b following treatment
The effect of different doses of ovarian steroid hormones
on the brain level of TGF-b after TBI is shown in Fig. 4.
Fig. 4a shows that in both the E1 (7.8 ±0.3 ng/mL) and P1
(5.6 ± 0.2 ng/mL)-treated groups, the brain level of TGF-b
significantly increased compared with the vehicle-treated
group (0.8 ± 0.2 ng/mL, p < 0.001). There were also statisti-
cal differences between the E2 (6.4 ± 1 ng/mL, p < 0.01)
and P2 (4.5 ± 0.8 ng/mL, p < 0.05)-treated groups compared
with the vehicle-treated group. The TGF-b level in the E1
group was also significantly higher than in the P1 group
(p < 0.01).
The change in the brain level of TGF-b in the group
treated with a low dose of estrogen compared with the ve-
hicle group is shown in Fig. 4b. The TGF-b level in the E1-
treated group significantly increased (937.71% ± 202.9)
compared with the E1+P1 (–37.99% ± 6.26) and E1+P2
(–32.27% ± 5.05)-treated groups (p < 0.001). Fig. 4c
shows the effect of a high dose of estrogen on the brain
level of TGF-b compared with the vehicle-treated group.
Changes in TGF-b in the E2-treated group (821.72% ±
193.94) were also significantly higher than in the E2+P1
(–6.92% ± 3.67) and E2+P2 (–19.15% ± 16.68)-treated
groups (p < 0.001). The TGF-b level in the case of a com-
bined administration of estrogen and progesterone shows a
decrease, instead of an increase.
Alternation in brain levels of sex steroid hormones
Table 1 shows brain levels of 17b-estrogen and progester-
one 24 h after TBI. The brain level of 17b-estrogen in the
E2 (608.7 ± 94.3 pg/mL) and E2+P1 (568.1 ± 53.8 pg/mL)-
treated groups was higher than in the vehicle-treated group
(333.4 ± 10.6 pg/mL, p < 0.001). There was also a signifi-
cant difference (p < 0.001) between the E2+P1 and E1+P2
(367.7 ± 10.7 pg/mL)-treated groups.
The brain level of progesterone showed a significant dif-
ference (p < 0.01) in the P2 (27.7 ± 3.5 ng/mL) compared
with the vehicle-treated groups (12.3 ± 0.5 ng/mL).
Discussion
Secondary trauma cascades are activated after TBI. They
include severe brain inflammatory responses, which play a
Fig. 4. (a) Effect of estrogen or progesterone following traumatic
brain injury (TBI) on brain level of TGF-b (ng/mL) in ovariecto-
mized (OVX) rats (n = 7 in each group). *, p < 0.05, P2 group vs.
vehicle. **, p < 0.01, E2 group vs. vehicle. ***, p < 0.001, E1 and
P1 groups vs. vehicle. # #, p < 0.01, E1 vs. P1 group. (b) Changes
in the percentage of brain level of TGF-b after TBI compared with
vehicle, in OVX rats (n = 7 in each group). {{{, p < 0.001, E1 vs.
E1+P1 or E1+P2 groups. (c) Changes in the percentage of brain le-
vel of TGF-b after TBI compared with the vehicle, in OVX rats (n
= 7 in each group). # # #, p < 0.001, E2 vs. E2+P1 or E2+P2
groups. Veh, vehicle; E1, physiological dose of estrogen; E2, phar-
macological dose of estrogen; P1, physiological dose of progester-
one; P2, pharmacological dose of progesterone; E1+P1,
physiological dose of estrogen + physiological dose of progester-
one; E1+P2, physiological dose of estrogen + pharmacological dose
of progesterone; E2+P1, pharmacological dose of estrogen + phy-
siological dose of progesterone; E2+P2, pharmacological dose of
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role in the pathology of traumatic injury. BBB disruption,
edema formation, activation of resident glial cells, and the
release of inflammatory cytokines also form part of delayed
responses to traumatic injury (de Vries et al. 1997; del
Zoppo and Hallenbeck 2000). The present study shows that
progesterone and estrogen administered alone and in combi-
nation cause a reduction in brain edema as well as an inhib-
ition of BBB damage in TBI. The inflammatory effect may
be mediated by affecting the brain levels of cytokines.
Both the therapeutic low dose (physiological dose) and
the high dose (pharmacological dose) of estrogen lead to a
reduction in water and Evans blue content. On the other
hand, both doses of progesterone have an inhibitory effect
on water content, while only the physiological dose of pro-
gesterone was able to inhibit Evans blue content. The great-
est inhibitory effect was observed with the pharmacological
dose of estrogen, which reduced 10.2% and 24.2% of the
water content and the Evans blue content, respectively.
The inhibitory effect of estrogen on water content was
abolished when a low dose of estrogen was used along with
a high dose of progesterone (E1+P2), while the combination
of E1+P1 did not show any changes. Co-administration of
E2+P1 or E2+P2 led to a reduction of the inhibitory effect
of estrogen. The inhibitory effect of estrogen on Evans blue
content was reduced when E1+P1 was used, but any changes
in the inhibitory effect of estrogen were not seen in the
E1+P2 group. These results indicated that the inhibitory ef-
fect was not only abolished, but also inverted when high
doses of estrogen and progesterone were used together
(E2+P2). In addition, this study suggests that the effect of
progesterone on water and Evans blue content is dose de-
pendent. We also showed a significant difference in the in-
hibitory effect between the E1+P1- and E1+P2-treated
groups for water content and between the E2+P1- and
E2+P2-treated groups for Evans blue.
There are several probable mechanisms by which sex ste-
roids could reduce the formation of brain edema that result
from inflammatory response. These include as scavengers
of free radicals (Gibson et al. 2005; Hoffman et al. 2006),
improvement of cell viability and reduction of edema forma-
tion (Roof et al. 1997), binding to GABAA receptors, and
modulating their functions (Baulieu et al. 1996). In addition,
these hormones might decrease brain edema by acting on
the BBB. The useful effects of steroids are not only limited
to the nerve cells but also expand to the endothelial cells.
Since the endothelium is one of the most important parts of
the BBB (Razandi et al. 2000), the protective effects of ste-
roids on the endothelial cells may enable them to protect the
BBB against TBI. Estrogen reduces the damage to the BBB
by inhibiting the expression of matrix metalloproteinase-2
(MMP-2), MMP-9, cyclooxygenase (Liu et al. 2005), and
vascular endothelial growth factor (VEGF) effect, after brain
ischemia (Chi et al. 2004). Progesterone also reduces brain
edema by decreasing the permeability of the BBB (Gibson
et al. 2005).
The effect of the E2+P1 treatment on the reduction of
Evans blue content might be related to the elevation in brain
estrogen level (only in this group, compared with the ve-
hicle), because water and Evans blue content were reduced
in all groups that administered progesterone and estrogen
alone, except in the P2-treated group. Furthermore, the
greatest effect of the pharmacological dose of estrogen com-
pared with the other 3 therapeutic groups and the vehicle
might be related to the highest brain level of estrogen.
With a pharmacological dose of progesterone, which
shows a high level of this steroid hormone within the brain,
Evans blue content increased, which means the low dose of
progesterone inhibits Evans blue content, whereas its high
dose increases it.
E1+P1 treatment caused the brain edema to decrease
without decreasing the BBB; this finding is consistent with
other studies that have reported that sex steroids can reduce
brain edema while the BBB is intact (Betz and Coester
1990), or that these steroids reduce brain edema by the other
mechanisms, such as the antioxidant mechanism (Gibson et
al. 2005; Hoffman et al. 2006). The present results show the
inhibition of water content (decreasing of the brain edema)
following administration of progesterone and estrogen alone,
but that the water content elevates following administration
of the hormones combined. Furthermore, if a decrease in
BBB disruption is desired, the administration of either pro-
gesterone or estrogen and a combination of the hormones,
such as E1+P2 and E2+P1, could be helpful.
Our study also showed that a brain level of IL-1b is in-
creased following TBI (data not shown). This finding is con-
firmed by previous studies (Lenzlinger et al. 2001; Kamm et
al. 2006; Chen et al. 2008). In addition, our results showed
Table 1. Change in brain concentrations of 17b-estradiol and progesterone in different groups of study, 24 h after traumatic brain injury
(TBI).
Hormone Group
Veh E1 E2 P1 P2 E1+P1 E1+P2 E2+P1 E2+P2
17b-stradiol
(pg/ml)
333.4±10.6 365±5.2 608.7±94.3a 339.9±14.9 336±11.6 451.2±64.05 367.7±10.7 568.1±53.8b 487.5±36.7
progesterone
(ng/mL)
12.3±0.5 15.3±4.3 20.5±2.1 14.8±1.6 27.7±3.5c 15.87±1.06 17.68±2.26 16.42±1.84 19.7±2.3
Note: Veh, vehicle; E1, physiological dose of estrogen; E2, pharmacological dose of estrogen; P1, physiological dose of progesterone; P2, pharmacologi-
cal dose of progesterone; E1+P1, physiological dose of estrogen + physiological dose of progesterone; E1+P2, physiological dose of estrogen + pharmacolo-
gical dose of progesterone; E2+P1, pharmacological dose of estrogen + physiological dose of progesterone; E2+P2, pharmacological dose of estrogen +
pharmacological dose of progesterone. Data are presented as mean ± SEM (n = 7 in each group).
aSignificant difference between the E2-treated group and the vehicle group (p < 0.001).
bSignificant difference between the E2+P1-treated group and the vehicle or E1+P2-treated groups (p < 0.001).
cSignificant difference between the P2-treated group and the vehicle group (p < 0.01).
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that both doses of estrogen could reduce (27%) the level of
IL-1b. This reducing effect of estrogen on the level of IL-1b
is associated with a decrease in gene expression and maxi-
mum production of the cytokines (Hans et al. 1999).
In addition, nervous damage resulting from TBI is inhib-
ited by controlled production of IL-1b (Lu et al. 2007). Ad-
ministration of IL-1b antagonisms after TBI leads to a
reduction of nervous inflammation; therefore, estrogen-in-
duced changes in the brain level of IL-1b could suggest a
mechanism that mediates anti-inflammatory and other neu-
roprotective effects. The lowering effects of estrogen on the
level of IL-1b have been confirmed by other investigators,
too (Yuan et al. 2002; Houdeau et al. 2007). It has also
been confirmed by a number of studies, which reported that
progesterone has no effect on the level of IL-1b (Holmin
and Ho¨jeberg 2004; Gibson et al. 2005; Jo¨nsson 2007);
therefore, the anti-inflammatory effect of progesterone
should be performed by the other mechanisms (Lenzlinger
et al. 2001; Gibson et al. 2005; Hoffman et al. 2006).
On the other hand, it has also been reported that proges-
terone causes a reduction in IL-1b (He et al. 2004; Gibson
et al. 2005; Chen et al. 2008) and the increasing effect of
estrogen on the level of IL-1b following TBI (Cutolo et al.
2006) is not similar to the result of the current study. The
discrepancy between our results and previously reported
data could be due to various factors, such as type of injury,
severity, dose and time of administration of hormones, and
type of solvent used. In addition, the combination of low
doses of estrogen and progesterone (the E1+P1-treated
group) could decrease the level of IL-1b more than the E1-
treated group, but statistically, the differences were not sig-
nificant, while the difference between this group (E1+P1)
when compared with the value obtained for the E1+P2-
treated group became significant. This means that the co-
administration of a high dose of progesterone and a low
dose of estrogen (E1+P2) leads to a decrease in the inhib-
itory effect of estrogen on IL-1b. A significant effect on
IL-1b production was observed when high doses of estro-
gen and progesterone (E2+P2) were administered. These
data correlated well with the results obtained from the
Evans blue and water contents. These data could suggest
that the reduction of IL-1b in the E1+P1- and E2+P1-
treated groups, and less so in the E1+P2-treated group,
might be one of the mechanisms that reduced brain edema
by a combination of estrogen and progesterone. Further-
more, our data showed that the differences between the
E1+P1- and E1+P2-treated groups, or between the E2+P1
and E2+P2-treated groups, were statistically significant. It
can be concluded that the reducing effects of the combined
groups on the IL-1b level is dose dependent, like the ef-
fects observed on the water and Evans blue contents. Pre-
viously, it was reported that the neuroprotective effects of
progesterone on experimental stroke are dose and time de-
pendent, while a physiological (low) dose of progesterone
plays a protective role in ischemic female rats (Murphy et
al. 2002) and decreases edema (Hoffman et al. 2006), but
its high dose has no effect. Progesterone in the absence of
estrogen led to an elevation of inflammation, but when
used with estrogen, it had a powerful anti-inflammatory
effect (Liu et al. 2005) by reducing the IL-1b level (Yuan
et al. 2002), or inhibiting IL-1b action (Schaefer et al.
2005).
The present study indicates that both doses of estrogen or
progesterone cause the level of TGF-b to increase following
TBI, but the estrogen has a more powerful effect than that
of progesterone. Previous studies indicated that the anti-in-
flammatory actions of TGF-b are dominant and, as the anti-
inflammatory effect of TGF-b is probably mediated by con-
trolled production of IL-1b, TNF-a, and free radicals of oxy-
gen (Chiaretti et al. 2008). The increasing TGF-b within the
brain might be one of the mechanisms of the anti-inflamma-
tory effect of steroids, as reported previously (Hatthachote
and Gillespie 1999; Gibson et al. 2005). The hormones in-
crease the level of TGF-b by changing the level of IL-1b
(Hoffman et al. 2006) and releasing the amount of cytokines
from brain and blood cells, and preventing damage to the
BBB (Lenzlinger et al. 2001).
In the combined groups, co-administration of estrogen and
progesterone leads to a reduction of their effects on the
brain level of TGF-b. Most of these reductions were seen in
the E1+P1- and E1+P2-treated groups. These data suggest
that the effect is decreased or abolished when a high dose
of estrogen is used in the combined groups. It is also re-
vealed that the effects of progesterone in combined groups
are not dose dependent. Based on the results of this part of
the study, a co-administration of estrogen and progesterone
is not recommended when the aim is increasing the level of
TGF-b.
Overall, the present study showed that the administration
of different doses of estrogen or progesterone alone (except
the pharmacological dose of progesterone) leads to prevent-
ing BBB disruption following TBI. In addition to other neu-
roprotective mechanisms of estrogen, decreasing the brain
level of IL-1b and increasing the level of TGF-b can be con-
sidered one of the mechanisms of the anti-inflammatory ef-
fects of different doses of estrogen. Progesterone also has an
anti-inflammatory effect, which is probably mediated by in-
creasing TGF-b, besides its other mechanisms. Our results
also showed that co-administration of estrogen and a phar-
macological dose of progesterone can decrease the neuro-
protective effects of estrogen, while such combination does
have an inhibitory effect on brain edema. The inhibitory ef-
fects of the combined groups on brain edema are consistent
with their inhibitory effects on increasing the level of TGF-b
and reducing the level of IL-1b. It is necessary to follow up
this study with an investigation of which type of mecha-
nisms and what receptors are mediated in the interaction be-
tween sex steroids and the cytokines.
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